Results suggest that although silymarin monotherapy is not as effective as doxycycline for the treatment of acne vulgaris, it can be a therapeutic option.
The antimicrobial activity of nonantibiotic acne agents may provide protection against a background of increased drug-resistant bacteria.
Photodynamic therapy was shown to have beneficial effects on inflammatory acne vulgaris and can be widely used to treat inflammatory acne vulgaris in clinic.
Data demonstrate the positive effect of weekly adalimumab treatment on incidence of hidradenitis suppurativa disease flare, time to flare, and duration of flare.
A study reveals the potential role of topical ketoconazole monotherapy as a viable acne treatment without concern for antibiotic resistance.
Transplantation of the beneficial strains of Cutibacterium acnes did not lead to deterioration of the acne lesions and clinical improvements were observed in comedone counts when comparing end-of-treatment with the baseline assessments.
A more efficient objective tool to standardize acne severity and outcome measurements shows promise.
Treatment with anti-inflammatory dose doxycycline plus combination adapalene and benzoyl peroxide gel improved symptoms of severe acne, including a reduction in lesion and nodule counts.
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for clascoterone cream 1% for the treatment of acne.
Minocycline foam 4% (Amzeeq; Foamix) appears to be safe and effective for moderate-to- severe acne, according to findings from a long-term, open-label safety study.